Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 674-679

  Guerrero, A ^a   Gavila P ^a   Folkerd, E ^a   Ortiz, B ^b   Martinez F ^b   Garcia A ^b   Climent, M A ^a   Ruiz V ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Amenorrhea chemically induced; Aromatase inhibitor; Estradiol blood; Ovarian function

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTRADIOL; EXEMESTANE; FLUOROURACIL; FOLLITROPIN; MUELLERIAN INHIBITING FACTOR; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; AMENORRHEA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED AMENORRHEA; DISEASE FREE SURVIVAL; DRUG SUBSTITUTION; ECHOGRAPHY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HORMONE DETERMINATION; HUMAN; IMMUNOASSAY; INCIDENCE; MAJOR CLINICAL STUDY; MENOPAUSE; MULTIVARIATE ANALYSIS; OVARY FUNCTION; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT OUTCOME; VAGINA;

EID: 84874562380     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds464     Document Type: Article

References (22)

1. Burstein HJ, Prestrud AA, Seidenfeld J et al.. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28: 3784-96.
2. Goldhirsch A, Wood WC, Coates AS et al.. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2011; 22: 1736-47.
3. Geisler J, Haynes B, Anker G et al.. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002; 20: 751-7.
4. Dunbier AK, Anderson H, Ghazoui Z et al.. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J Clin Oncol 2010; 28: 1161-7.
5. Pritts EA. Letrozole for ovulation induction and controlled ovarian hyperstimulation. Curr Opin Obstet Gynecol 2010; 22: 289-94.
6. Ganz PA, Land SR, Geyer CE, Jr et al.. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 2011; 29: 1110-6.
7. Smith IE, Dowsett M, Yap YS et al.. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006; 24: 2444-7.
8. Burstein HJ, Mayer E, Patridge AH et al.. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer 2006; 7: 158-61.
9. Landgren BM, Collins A, Csemiczky G et al.. Menopause transition: Annual changes in serum hormonal patterns over the menstrual cycle in women during a nine-year period prior to menopause. J Clin Endocrinol Metab 2004; 89: 2763-9.
10. Dowsett M, Folkerd E. Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res 2005; 7: 1-4.
11. Lee JS, Ettinger B, Stanczyk FZ et al.. Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2006; 91: 3791-7.
12. Dowsett M, Goss PE, Powles TJ et al.. Use of the aromatase inhibitor 4hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res 1987; 47: 1957-61.
13. Petrek J, Naughton M, Case D et al.. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006; 24: 1045-1051.
14. Rose DP, Davis TE. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res 1980; 40: 4043-7.
15. Rossi E, Morabito A, Di Rella F et al.. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE Trial. J Clin Oncol 2009; 27: 3192-3197.
16. La Marca A, Malmusi S, Giulini S et al.. Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 2004; 19: 2738-41.
17. van Rooij IA, Tonkelaar I, Broekmans FJ et al.. Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 2004; 11: 601-6.
18. La Marca A, Broekmans FJ, Volpe A et al.. Anti-Mullerian hormone (AMH): what do we still need to know? Hum Reprod 2009; 24: 2264-75.
19. Dieudonné AS, Vandenberghe J, Geerts I et al.. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor. Menopause 2011; 18: 821-4.
20. Yu B, Douglas N, Ferin MJ et al.. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 2010; 116: 2099-105.
21. Geisler J, King N, Anker G et al.. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998; 4: 2089-93.
22. Goss PE, Ingle JN, Martino S et al. Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial. Cancer Res 69: 24S, 2009 (suppl); (Abstr 13).